U.S. President Donald Trump said in a 5 Aug. interview with CNBC that his administration will impose a “small” tariff on imported pharmaceuticals and progressively raise the levy to 150% in about a year and to 250% within 18 months. Trump framed the move as a bid to bring drug manufacturing back to the United States. The planned duties emerge from a Section 232 national-security probe launched in April. Trump has also sent letters to 17 global drugmakers demanding binding commitments to reduce U.S. prices by 29 Sept., warning that failure to do so could trigger additional penalties. Industry groups have cautioned that steep tariffs could disrupt supply chains and raise costs for patients. Separately, the president said his administration will announce tariffs on semiconductors and chips “within the next week or so,” describing the category as a strategic priority distinct from pharmaceuticals. The Commerce Department has been studying the sector since April, and new levies could raise costs for data-center operators and hardware makers such as Microsoft, Amazon and Meta. The twin measures extend Trump’s wider campaign to repatriate critical manufacturing and reshape global trade flows.